Comunicados de prensa de Faron Pharmaceuticals

(PR-inside.com) First clinical evaluation of bexmarilimab plus nivolumab in patients with anti-PD-1-resistant solid tumors TURKU, FI / ACCESS Newswire / October 1, 2026 / Faron Pharmaceuticals Ltd. (H…

(PR-inside.com) TURKU, FI / ACCESS Newswire / September 30, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces t…

(PR-inside.com) TURKU, FI / ACCESS Newswire / September 17, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to…

(PR-inside.com) Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) will publish its half-year financial results for January-June 2026 on Wednesday 26 August 2026 TURKU, FI / ACCESS Newswire / August 19, 2026…

(PR-inside.com) Inside Information: After a median follow-up of 14.9 months, median overall survival has not yet been reached in frontline HR MDS without TP53 mutations, nor has it yet been reached fo…

(PR-inside.com) Investigators update from BLAZE in checkpoint-resistant solid tumors highlights continued progress across Faron's expanding Investigator-Initiated Trial (IIT) portfolio TURKU, FI / ACC…

(PR-inside.com) TURKU, FI / ACCESS Newswire / May 28, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapi…

(PR-inside.com) Faron has terminated the liquidity providing agreement with Lago Kapital TURKU, FI / ACCESS Newswire / May 6, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage…